Vascular Endothelial Growth Factor (VEGF) Antibodies Market report provides key enumeration on the Market status of the Vascular Endothelial Growth Factor (VEGF) Antibodies manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The research was conducted using an objective combination of primary and secondary information including inputs from key participants in the Vascular Endothelial Growth Factor (VEGF) Antibodies industry. It delivers important information to identify and analyse the market need, market Growth and competition.
The global Vascular Endothelial Growth Factor (VEGF) Antibodies Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Vascular Endothelial Growth Factor (VEGF) Antibodies Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.
Vascular endothelial growth factor (VEGF) is the signal protein, which helps in formation of the novel blood vessels by a process called as angiogenesis. The vascular endothelial growth factor is the part of various pathological researches and processes often are performed to develop novel therapies with the use of those factors for disorders including cancer. General functions of the vascular endothelial growth factor are embryonic development, novel blood vessel formation, and as the bypass for the blocked vessels. However, the VEGF overexpression often culminates in fatal disease including cancerous cells. Since the solid tumors need additional supply of blood for keeping its functioning, the VEGF overexpression serves this purpose via angiogenesis. The family of VEGF has 5 members including VEGF-D, VEGF-C, VEGF-B, VEGF-A, and Placenta Growth Factor (PGF). From these growth factors, the VEGF-A is accountable for angiogenesis as well as the processes related to endothelial cells. The VEGF-A binds with VEGF receptors upon endothelial cells, triggering the tyrosine kinase pathway resulting in angiogenesis. The VEGF-A was observed to be related to poor prognosis within several cancers, age-related macular degeneration, and diabetic retinopathy.
Vascular Endothelial Growth Factor (VEGF) Antibodies Market Drivers
Increasing incidence of diseases including macular degeneration and cancer is expected to drive the global vascular endothelial growth factor antibodies market growth over the forecast period. In 2017, as per the American Cancer Society, cancer accounted for the second leading cause of death within the U.S., resulting in around 1 in every four deaths. Innovative therapies including angiogenesis, inhibitors, and monoclonal antibodies are targeted therapies which are highly specialized, directly targeting the cancer cells. The targeted therapies are being highly preferred, due to the benefits (lesser side effects) provided by targeted therapies rather than the conventional therapies including chemotherapy. Moreover, robust VEGF antibodies pipeline is expected to drive growth of the global vascular endothelial growth factor antibodies market during the forecast period. For instance, the Brolucizumab (Alcon) is within clinical trials of phase 3, Abicipar (Allergan Plc) is within clinical trials of phase 3, and the RG7716 (Genentech) is within clinical trials of phase 2, all of them indicated for age-associated macular degeneration. Furthermore, Tecentriq by Roche received the status of priority review by the U.S. FDA, in May 2018, for treating people having metastatic non-squamous non-small cell lung cancer. The therapies already available within the market have demonstrated enhanced clinical outcome for cancer and age-related macular degeneration (AMD). For instance, the Lucentis, and Avastin have demonstrated significant enhancements within medical outcomes for associated indications including cancer. The therapies have dragged interest of the manufacturers for carrying out further research within this category that is stated in terms of the number of agents within the pipeline. Successful drugs including Lucentis and Avastin allow manufacturers for investing in R&D of these therapies, for generating revenues later on with providing the advantages to patients. Such aspects are expected to drive global vascular endothelial growth factor antibodies market growth over the forecast period.
However, rising costs of such medications, subsequent launches, and biosimilar research, are expected to restrain the global vascular endothelial growth factor antibodies market growth. Mvasi (bevacizumab-awwb), which is the Avastin (bevacizumab) biosimilar has already been approved by the U.S. Food & Drug Administration, in December 2017. Furthermore, the Avastin (bevacizumab) biosimilar was approved by the European Commission in January 2018.
Vascular Endothelial Growth Factor (VEGF) Antibodies Market Insights
Based on region, the North America and Europe regions are expected to register robust growth in the global vascular endothelial growth factor antibodies market during the forecast period. North America includes the existence of leading players who are focused on R&D of such therapies. Manufacturers including Genentech and Novartis (Europe) have such therapies within pipeline which are expected to step foot in the market during the forecast period. Asia Pacific is expected to witness modest growth, due to high prices of such therapies and reasonably low overall availability in this region. Sophisticated facilities of insurance including Medicare and Medicaid aren’t present in emerging economies owing to which people cannot afford expensive medical treatment within these regions. The insurance facilities, however are expected to propel growth of the global vascular endothelial growth factor (VEGF) antibodies market in North America.
Major players functioning in the global vascular endothelial growth factor (VEGF) antibodies market are Genentech, Inc., Exelixis, Inc., Novartis, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Bayer Pharma AG, Valeant Pharmaceuticals, ThromboGenics, Inc., and Ceres Oncology Pty Ltd.
Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Taxonomy
Based on Drug –
-
Cometriq
-
Avastin
-
Tecentriq
-
Eylea
-
Cyramza
-
Jetrea
-
Lucentis
-
Macugen
-
Others
Based on Route of Administration-
-
Intravenous
-
Oral
-
Intravitreal
Based on Application-
-
Ophthalmology
-
Cancer
-
Others
Based on Distribution Channel-
-
Online Pharmacies
-
Retail Pharmacies
-
Hospital Pharmacies
Based on Region-
-
North America
-
Asia Pacific
-
Europe
-
Latin America
-
Africa
-
Middle East
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1614
Reasons to Purchase this Report
• Current and future of global Vascular Endothelial Growth Factor (VEGF) Antibodies Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
About Us
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact Us
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837